Archive: Company News
TolerogenixX Receives Approval to Start Phase IIb Trial for its Immune Tolerance-Inducing MIC-Lx Cell Therapy
— Multi-centric clinical study in patients with stage 5 chronic kidney disease (CKD) receiving a living donor kidney
— Study of MIC-Lx cell treatment, a potentially curative approach to achieve sustained immune tolerance in transplanted and autoimmune patients as shown in previous Phase Ib study
TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, today announced that the German regulatory authority Paul-Ehrlich-Institut has approved a Phase IIb clinical trial for TolerogenixX’s MIC-Lx cell therapy designed to induce immune tolerance. Read more…
Omnix Medical Advances Novel Anti-Infective Program into Clinical Development
– Entirely novel therapeutic principle to combat alarming worldwide rise of antimicrobial resistance (AMR)
Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced it received approval by Dutch authorities to initiate a Phase I clinical trial with its lead compound OMN6 in healthy volunteers. The trial will be conducted in Groningen, The Netherlands.
OMN6, the lead compound of Omnix, is a first-in-class antimicrobial peptide for the treatment of life-threatening infections caused by Gram-negative bacteria. Read more…
Neonatal Diagnostics Company InfanDx AG Closes Oversubscribed Second Tranche of Series A
- Second tranche of approximately EUR 2 million additional funding raised in response to unsolicited investor interest
- Transaction oversubscribed by more than 50%
- Funding provides further financial runway and flexibility as Company progresses product development on schedule
InfanDx AG, a privately-held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, today announced the second closing of its Series A financing round, raising approximately EUR 2 million in additional proceeds from new and existing investors. A first closing of the Series A totaling about EUR 4 million was completed in July 2021. The second tranche of this Series A was placed under the same conditions as the first tranche and oversubscribed by more than 50% based on strong investor interest.
InfanDx AG: Clinical Findings from Prospective AAMBI Study Highlight Need for Better Early Detection of Neonatal Brain Injury
— Scientific poster presented at the 13th International Newborn Brain Conference
— Data demonstrate the importance of novel and reliable diagnostic markers for the early detection of Hypoxic-Ischemic Encephalopathy (HIE) in newborns
InfanDx AG, a privately-held diagnostics company focusing on novel solutions for acute and critical care of newborns, today announced the presentation of a scientific poster on clinical findings of the prospective AAMBI study sponsored by the Company. The poster authored by Prof. Axel Franz (University of Tuebingen, Germany), Prof. Hacer Yapıcıoğlu Yıldızdaş (Cukurova University, Adana, Turkey), Prof. Peter Bartmann (University of Bonn, Germany) and further members of the AAMBI study group was featured yesterday at the 13th International Newborn Brain Conference hosted by the Newborn Brain Society, an organization focused on advancing newborn brain care through international multidisciplinary collaboration, education, and innovation.